☰

Eligo Bioscience

Connecting R&D discovery to clinical-grade manufacturing

Industry
Biotechnology (Microbiome Gene Editing)
Headquarters
Paris, France
Public information as of
March 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Eligo Bioscience's published strategy and is not endorsed by, or produced in cooperation with, Eligo Bioscience. Company website

Strategic priorities

Eligo Bioscience is industrialising its Eligobiotics® platform, a set of engineered phage-derived capsids that carry CRISPR-Cas9 payloads into the microbiome for in-vivo gene editing. Founded in 2014 as a spin-off from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University, the company runs research and discovery out of Paris and manufactures through the Biose Industries CDMO in Cantal, France. Lead candidate EB005 is being advanced for immuno-dermatology indications, with EB003 in STEC (Shiga toxin-producing E. coli) infection as a second program.

The capital stack is configured for that industrialisation. A $35 million Series B expansion led by Sanofi Ventures closed in December 2023, and a $5 million France 2030 grant followed in May 2025, earmarked for bioproduction scale-up. Sanofi Ventures has stated its investment is tied to the adoption of advanced AI and digital technologies across the R&D ecosystem, which frames the digital work as part of the funding rationale rather than a follow-on concern.

Manufacturing uses complex microbial fermentation with hard-to-culture obligate anaerobes, and the production system at Biose has to hold phage titers and payload encapsulation within tight ranges across batches. The current way of working is Benchling for R&D construct and experiment records on one side, and SCADA/PLC (Supervisory Control and Data Acquisition / Programmable Logic Controller — the industrial control systems on the bioreactor floor) output from production reactors on the other, with data moving between the two estates through Excel and ad-hoc file transfers rather than through a shared platform.

Lead programs EB005 and EB003 are advancing toward FDA and EMA clinical trials. The FDA's 2026 reforms to CMC requirements for cell and gene therapies still require clear comparability data when manufacturing changes occur, which puts the burden of evidence on the data platform that connects R&D construct design to GMP (Good Manufacturing Practice) batch output. The France 2030 grant is also tied to delivery on efficient and sustainable manufacturing milestones that must be measurable on the line rather than reconstructed after the fact.

Challenges we see

  • Operations Manufacturing

    Scaling microbial fermentation at the CDMO without losing batch definition

    Eligobiotics® are non-replicative engineered phage capsids produced by microbial fermentation with sensitive bacterial strains, including hard-to-culture obligate anaerobes, at the Biose Industries CDMO site. Minor variances in raw materials, gas composition and feed regime can change phage titers and payload encapsulation by enough to affect downstream editing efficiency.

    Where the production host is hard-to-culture and the operating envelope is narrow, the test of a fermentation run is whether it can be repeated with the same parameters, and the path to repetition is to capture every critical variable at the line rather than to rely on operator recall.

  • Data Integration

    Connecting R&D Benchling records to CDMO manufacturing data

    Benchling holds the DNA construct design and experiment records for SSAM, GEM and FAME modalities on the R&D side, while bioreactor and analytical-instrument output from Biose Industries stays inside the manufacturing floor. The transfer between the two estates currently runs through Excel and ad-hoc file drops.

    Where the construct record and the production record live in different systems, the time to trace a release result back to the construct and process that produced it is the time it takes to assemble the evidence by hand, which puts CMC comparability on a manual path.

  • Digital Operations

    Building operator confidence in automated pipelines

    As Eligo scales its robotics pipelines within the Discovery and Automation unit, scientists who are used to bench-tethered monitoring keep automated features in manual mode and run visual checks alongside the system. The friction is most visible when an automated signal does not match the bench result and the operator decides which to trust.

    Where the same work is being done twice, once by the automation and once by the operator, the value of the automation is measured by the trust it can earn in the moments when the two signals disagree, so transparency and auditability of the automated signal become the operational requirement.

  • Compliance Regulatory

    Producing demonstrable CMC evidence under FDA and EMA scrutiny

    Advancing EB005 and EB003 into clinical trials brings both candidates under FDA and EMA scrutiny on Chemistry, Manufacturing and Controls. The FDA's 2026 reforms for cell and gene therapies still require clear comparability data when manufacturing changes occur, and the work is performed at a CDMO rather than on Eligo's own floor.

    Where comparability is the regulatory question, the answer has to be assembled from the same data set that produced the batches, which means the data system has to capture batch history and process state continuously rather than assemble it on request for an inspection.

  • Quality Manufacturing

    Holding phage titers and payload encapsulation steady across batches

    Consistency in phage titers and payload encapsulation is critical across SSAM, GEM and FAME modalities, where minor variances in capsid production can visibly reduce in-vivo editing efficiency. Biose Industries is exposed to foam formation in its bioreactors, which blocks filters, raises contamination risk and causes batch loss.

    Where the cost of a failed batch is the loss of sensitive biological material and the delay of a clinical program, the operating practice is to read process signals as the batch runs rather than to confirm them in a later report, so the population under review becomes the batch that actually deviated.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Reading fermentation KPIs while the batch runs

    Biological KPIs (viable cell density, cell-specific productivity, phage titers) at Biose Industries are calculated after the run completes, in Excel, from data stitched from scales, sensors and offline samples. A deviation only shows up days after the batch has finished.

    Connecting bioreactor and analytical data into one time-series model and overlaying the current batch against validated historical batches lets a deviation appear against the batch that is still running, which gives the quality function the same view of the run that the engineers have.

    • Eligo Bioscience press release, France 2030 grant, May 2025
    • Biose Industries, Scaling hard-to-culture multi-strain LBPs, 2025

  2. Joining Benchling and Biose floor data into one platform

    Benchling holds R&D constructs and experiment records on one side; SCADA/PLC and analytical data from Biose Industries' bioreactors sit on the other. The connection between them runs through Excel and ad-hoc file transfers.

    An ontology-based data platform that defines the construct, process, batch, sample, result and lot entities once, and loads both estates against that model, gives Eligo and Biose a single shared view of the batch history that drives both comparability and release.

    • Benchling, Industry Spotlight: Eligo Bioscience, 2024
    • Eligo Bioscience, Series B expansion announcement, December 2023

  3. Detecting foam in bioreactors without contact

    Foam formation at Biose Industries blocks filters, raises contamination risk and causes batch loss. Manual visual checks are intermittent, slow and operator-dependent, and antifoam dosing is set by hand.

    External cameras with continuous image processing can detect foam levels and density in real time without contact with the culture, and feed a dosing loop that adjusts antifoam addition to what the culture actually needs, reducing both chemical use and batch-loss risk.

    • Biose Industries, Scaling hard-to-culture multi-strain LBPs, 2025
    • Eligo Bioscience, France 2030 grant announcement, May 2025

  4. Capturing laboratory and analytical data with ALCOA+ integrity

    Laboratory and analytical data at Eligo and Biose is split between paper, instrument printouts and LIMS (Laboratory Information Management System) entries, with manual transcription between them. ALCOA+ data integrity is the regulatory expectation for gene therapy submissions.

    Integrating balances, plate readers, qPCR (quantitative Polymerase Chain Reaction) instruments and chromatography systems into a Laboratory Execution System with direct instrument-to-LES (Laboratory Execution System) capture produces the audit trail and the structured record the FDA and EMA expect, with no manual transcription in the chain.

    • FDA, Reforms to Requirements for Cell and Gene Therapy Products, 2026
    • Eligo Bioscience, CMC appointment press release, 2024

  5. Drafting CMC and regulatory documents from a single evidence base

    CMC sections, comparability reports, batch records, IND and IMPD (Investigational Medicinal Product Dossier) content, and France 2030 milestone disclosures are drafted separately from the same captured measurements, by people who also have to keep the production line running.

    Narrow reviewable agents can draft each document from the same underlying records, check each draft against the relevant template and the controlled-document set before it enters a human review queue, and find every controlled document a standards change touches, with a named reviewer approving every output.

    • FDA, Reforms to Requirements for Cell and Gene Therapy Products, 2026
    • Eligo Bioscience, France 2030 grant terms, 2025

What we'd propose

  • Digital CDMO

    Real-time process intelligence for fermentation at Biose Industries

    Connect bioreactor and analytical data from Biose Industries into one time-series model, overlay the current batch against validated historical batches, and produce deviation alerts while the batch is still running, so the quality function sees the same view of the run that the engineers do.

    • Bioreactor and analytical data acquisition

      Data off the floor in one place

      Connect bioreactor controllers, scales, sensors and offline samples through OPC UA (Open Platform Communications Unified Architecture) or MQTT (Message Queuing Telemetry Transport — a lightweight messaging protocol widely used for industrial telemetry) so process values leave the equipment in a documented vendor-neutral form, ready to feed downstream models.

    • Real-time KPI calculation and Golden Batch overlay

      The current batch against the best one

      Compute viable cell density, cell-specific productivity and phage titers from the streaming data, and overlay the current batch against the best historical run for the same product so a deviation is visible in the same view the operators are already watching.

    • Smart alarm management

      Severity-graded deviation alerts

      Categorise process alerts by severity, surface only the ones that warrant operator action, and keep the full record available for review, so a real deviation is seen in minutes rather than buried in a shift-end report.

    • A deviation shows up against the batch that is still running, not the one that already shipped.
    • One set of process data serves manufacturing, quality and engineering instead of three separate extracts.
    • Golden Batch history is built up as the platform runs, not assembled by hand when a deviation occurs.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Ontology-based data platform joining Benchling and the Biose floor

    An ontology-based data platform that defines the construct, process, batch, sample, result and lot entities once, and loads both Benchling R&D records and Biose Industries' manufacturing output against that single model, so Eligo and the CDMO share a single view of the batch history.

    • Shared ontology across R&D and manufacturing

      One vocabulary for both estates

      Define construct, process, batch, sample, result and lot as explicit entities with agreed relationships, so Benchling records and Biose floor data describe the same artefacts in the same way and a query written once returns comparable answers across both.

    • Benchling and SCADA/PLC ingestion pipelines

      Loading both sides

      Build ingestion for Benchling constructs and experiment records on the R&D side and for the Biose bioreactor SCADA/PLC and analytical-instrument output on the manufacturing side, with schema validation at the boundary so a bad record fails loudly instead of being absorbed silently.

    • Analytics and retrieval on the combined model

      Questions without IT tickets

      Expose the combined model through dashboards and a retrieval layer so CMC, QA and process teams can ask questions of the construct-to-batch record without commissioning a new extract for each one.

    • The construct-to-batch evidence path is generated by the system rather than reconstructed for an inspection.
    • Comparability questions, which are the FDA's and EMA's central CMC question, are answered by a single query across the model.
    • New assays and new modalities attach to the same model rather than triggering another migration.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Computer-vision foam control for Biose bioreactors

    External cameras with continuous image processing installed on Biose bioreactors to detect foam levels and density in real time without contact with the culture, feeding a dosing loop that adjusts antifoam addition to what the culture actually needs.

    • Camera-based foam detection

      External cameras, no probes

      Mount external cameras on each bioreactor and run continuous image processing to detect foam levels and surface state, distinguishing slow-rising foam from a flash event without any invasive probe in the culture.

    • Closed-loop antifoam dosing

      Dose adjusted to what is seen

      Drive the existing antifoam pump from the foam signal so addition is proportional to what the camera sees, reducing chemical use and removing the manual override that operators fall back on.

    • Continuous 24/7 monitoring

      Coverage without operator presence

      Run the monitoring on a continuous basis so overnight and weekend batches are covered by the same system as the day shift, and an emerging event is logged with the time stamp and the image that produced it.

    • The batch-loss risk from a foam event is contained by an automated system rather than by who is on shift.
    • Antifoam consumption is reduced because dosing is driven by what the camera sees, not by a fixed rule.
    • A four-camera plus image-processing reference architecture is straightforward to expand to additional bioreactors in the Biose facility.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Laboratory Execution System with ALCOA+ data integrity

    An integrated Laboratory Execution System that captures results directly from instruments at Eligo and Biose, maps them onto the batch record with their own audit trail, and meets the ALCOA+ expectations in the FDA's cell and gene therapy guidance.

    • Direct instrument capture

      Results arrive with their provenance

      Connect balances, plate readers, qPCR instruments and chromatography systems so analytical results are captured with instrument identity, method version, sample identity and timestamp attached, rather than being read from a screen and typed into another system.

    • Sample and result lineage to the batch

      Result to batch to construct

      Map analytical results onto the batch record and the upstream construct record so the data behind a release decision is traceable to the analytical run that produced it, and to the construct that was fermented.

    • 21 CFR Part 11 audit trail

      Electronic records that stand up

      Implement electronic signature, versioning and audit-trail handling to 21 CFR Part 11 (the U.S. Code of Federal Regulations title 21 part 11 governing electronic records and electronic signatures), so the evidence chain is complete on the system rather than reconstructed for an inspection.

    • Manual transcription between instrument and LIMS is removed, along with the transcription errors that come with it.
    • The ALCOA+ evidence the FDA and EMA expect is generated by the lab workflow rather than assembled for the audit.
    • Sample and batch lineage is queryable, so an out-of-specification result can be traced back to the construct and process in a single step.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for CMC, comparability and regulatory document work

    Narrow reviewable agents that draft CMC sections, comparability reports, IND and IMPD content, batch record summaries and France 2030 milestone disclosures from the same shared evidence base, check each draft against its template and the controlled-document set before review, and find every controlled document a standards change touches. A named reviewer approves every output.

    • First drafts from the shared evidence base

      Drafts from system data

      Generate the first draft of a CMC section, a comparability report or a France 2030 milestone disclosure directly from the construct, batch and analytical records, so the author edits and judges rather than assembles and re-keys.

    • Template and completeness check

      Gaps found before review

      Check a draft against the relevant regulatory template and Eligo's own checklist before it enters the human review queue, returning missing or inconsistent sections so reviewers see documents that are already complete.

    • Change-impact search across the controlled document set

      Which documents a change touches

      When a regulatory standard, an SOP (Standard Operating Procedure), a specification or a process change is issued, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is established by search rather than by recollection.

    • Review queues move faster because documents arrive complete and in their template shape.
    • The scope of a regulatory or process change is established by search rather than by recollection.
    • Sustainability disclosures and batch records are produced from the same measurements as the release record, which makes them auditable rather than assembled.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Eligo Bioscience's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
IT/OT convergence 30 → 80
Benchling on the R&D side and Biose floor SCADA/PLC on the manufacturing side run as separate estates today, with Excel and ad-hoc file transfers between them. The work to converge them is the shared-ontology proposal rather than a rewrite of either side.
Process automation and control 45 → 80
The Discovery and Automation unit has pipelines in operation, but operators fall back to manual checks when the automated signal does not match the bench result. Raising automation adoption means making the automated signal trustworthy in the moments of disagreement.
Real-time analytics 25 → 75
Biological KPIs at Biose are calculated after the run completes; the live monitoring proposal closes the gap between data acquisition and KPI view, and the Golden Batch overlay makes the running batch comparable to the best historical run.
Regulatory and compliance digitalisation 35 → 85
Paper-based and fragmented digital systems at the lab and CDMO produce ALCOA+ compliance risk for upcoming FDA and EMA submissions. The Laboratory Execution System and the agents proposal are the two pieces that move this dimension forward.
Scale-up readiness 20 → 70
No virtual model of the fermentation process exists yet, so scale-up at Biose is guided by iterative physical experimentation. The real-time intelligence proposal collects the data that a future digital twin would be calibrated against.
Workforce digital fluency 40 → 75
The Discovery and Automation unit operates at the frontier of the company's digital skills, and the rest of the organisation is on a learning curve. The Laboratory Execution System and the shared-ontology platform both raise fluency through their day-to-day use.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of March 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Eligo Bioscience, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].